On Nov 05, major Wall Street analysts update their ratings for $Revvity (RVTY.US)$, with price targets ranging from $132 to $145.
Barclays analyst Luke Sergott maintains with a buy rating, and maintains the target price at $140.
Evercore analyst Vijay Kumar maintains with a buy rating, and adjusts the target price from $132 to $134.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $141 to $144.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $136 to $138.
KeyBanc analyst Paul Knight maintains with a buy rating, and adjusts the target price from $126 to $132.
Furthermore, according to the comprehensive report, the opinions of $Revvity (RVTY.US)$'s main analysts recently are as follows:
The firm noted that the primary area of weakness for Revvity in the third quarter was in instruments, with management adjusting the fourth quarter guidance to indicate that this trend is persisting.
Revvity reported third-quarter revenue and EPS that surpassed the consensus, displaying varied revenue performance. The company has conveyed a sense of steadiness within the pharmaceutical and biotech sectors, but has noted that spending on instruments by customers is still restricted, especially in China.
Here are the latest investment ratings and price targets for $Revvity (RVTY.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$Revvity (RVTY.US)$的評級，目標價介於132美元至145美元。
巴克萊銀行分析師Luke Sergott維持買入評級，維持目標價140美元。
Evercore分析師Vijay Kumar維持買入評級，並將目標價從132美元上調至134美元。
TD Cowen分析師Daniel Brennan維持買入評級，並將目標價從141美元上調至144美元。
貝雅分析師Catherine Ramsey Schulte維持買入評級，並將目標價從136美元上調至138美元。
KeyBanc分析師Paul Knight維持買入評級，並將目標價從126美元上調至132美元。
此外，綜合報道，$Revvity (RVTY.US)$近期主要分析師觀點如下：
以下爲今日6位分析師對$Revvity (RVTY.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
